company background image
MCRB logo

Seres Therapeutics NasdaqGS:MCRB Stock Report

Last Price

US$0.78

Market Cap

US$117.8m

7D

-6.1%

1Y

-86.1%

Updated

27 Mar, 2024

Data

Company Financials +

Seres Therapeutics, Inc.

NasdaqGS:MCRB Stock Report

Market Cap: US$117.8m

MCRB Stock Overview

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome.

MCRB fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Seres Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Seres Therapeutics
Historical stock prices
Current Share PriceUS$0.78
52 Week HighUS$6.87
52 Week LowUS$0.73
Beta2.27
1 Month Change-27.08%
3 Month Change-44.27%
1 Year Change-86.12%
3 Year Change-96.21%
5 Year Change-87.81%
Change since IPO-98.48%

Recent News & Updates

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Mar 23
Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Recent updates

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Mar 23
Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Jan 30

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Dec 18
Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Aug 31
Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Aug 09
Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Dec 28
Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Sep 01
Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Seres Therapeutics: What The Market Is Missing

Aug 19

Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M

Aug 03

Seres Therapeutics: The Good And The Challenging

Jul 12

Seres Therapeutics stock slips on $100M stock offering

Jun 30

Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Jun 16
Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens

Jun 09

Seres Therapeutics Is Playing A Long Game

Mar 06

Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02
Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Dec 27
Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Seres Therapeutics Molecular Data On SER-109 Looks Good

Oct 04

Seres Therapeutics: Here We Go Again

Sep 09

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Sep 03
Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Need To Know: Analysts Are Much More Bullish On Seres Therapeutics, Inc. (NASDAQ:MCRB) Revenues

Jul 03
Need To Know: Analysts Are Much More Bullish On Seres Therapeutics, Inc. (NASDAQ:MCRB) Revenues

Seres Therapeutics (MCRB) Presents At 2021 Jefferies Virtual Healthcare Conference - Slideshow

Jun 08

Seres Therapeutics gets FDA clearance for SER-155 IND trials

Jun 01

Broker Revenue Forecasts For Seres Therapeutics, Inc. (NASDAQ:MCRB) Are Surging Higher

May 20
Broker Revenue Forecasts For Seres Therapeutics, Inc. (NASDAQ:MCRB) Are Surging Higher

Seres Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 05

Is Seres Therapeutics (NASDAQ:MCRB) Using Debt In A Risky Way?

Apr 05
Is Seres Therapeutics (NASDAQ:MCRB) Using Debt In A Risky Way?

Shareholder Returns

MCRBUS BiotechsUS Market
7D-6.1%0.9%0.4%
1Y-86.1%10.3%28.8%

Return vs Industry: MCRB underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: MCRB underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is MCRB's price volatile compared to industry and market?
MCRB volatility
MCRB Average Weekly Movement11.5%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: MCRB's share price has been volatile over the past 3 months.

Volatility Over Time: MCRB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2010233Eric Shaffhttps://www.serestherapeutics.com

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection.

Seres Therapeutics, Inc. Fundamentals Summary

How do Seres Therapeutics's earnings and revenue compare to its market cap?
MCRB fundamental statistics
Market capUS$117.82m
Earnings (TTM)-US$113.72m
Revenue (TTM)US$126.33m

0.9x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MCRB income statement (TTM)
RevenueUS$126.33m
Cost of RevenueUS$145.86m
Gross Profit-US$19.53m
Other ExpensesUS$94.19m
Earnings-US$113.72m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.75
Gross Margin-15.46%
Net Profit Margin-90.02%
Debt/Equity Ratio-226.4%

How did MCRB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.